Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial AstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in the European… Read More
adMare BioInnovations welcomes Patricia Gauthier, President and General Manager of Moderna Canada, as the newest member of its Board of Directors. Patricia brings to adMare a wealth of leadership experience… Read More
Approval follows the positive opinion granted by European Committee for Medicinal Products for Human Use (CHMP) in July 2022 LUPKYNIS is the first oral medicine approved in both the U.S…. Read More
Vancouver, BC – September 19, 2022 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results… Read More
CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance1,2 Crohn’s disease is a chronic, systemic disease that manifests as inflammation… Read More
